Short-term ambulatory oxygen for chronic obstructive pulmonary disease

J M Bradley, B O'Neill, J M Bradley, B O'Neill

Abstract

Background: Ambulatory oxygen is defined as the use of supplemental oxygen during exercise and activities of daily living. Ambulatory oxygen therapy is often used for patients on long term oxygen therapy during exercise, or for non long term oxygen therapy users who achieve some subjective and/or objective benefit from oxygen during exercise. The evidence for the use of ambulatory oxygen therapy is extrapolated from two sources: longer term studies and single assessment studies. Longer term studies assess the impact of ambulatory oxygen therapy used at home during activities of daily living. Single assessment studies compare performance during an exercise test using oxygen with performance during an exercise test using placebo air.

Objectives: To determine the efficacy of ambulatory oxygen in patients with COPD using single assessment studies.

Search strategy: The Cochrane Airways Group COPD register was searched with predefined search terms. Searches were current as of March 2005.

Selection criteria: Only randomised controlled trials were included. Studies did not have to be blinded. Studies had to compare oxygen and placebo when administered to people with COPD who were undergoing an exercise test.

Data collection and analysis: Two reviewers (JB, B'ON) extracted and entered data in to RevMan 4.2.

Main results: Thirty one studies (contributing 33 data sets), randomising 534 participants met the inclusion criteria of the review. Oxygen improved all pooled outcomes relating to endurance exercise capacity (distance, time, number of steps) and maximal exercise capacity (exercise time and work rate). Data relating to VO2 max could not be pooled and results from the original studies were not consistent. For the secondary outcomes of breathlessness, SaO2 and VE, comparisons were made at isotime. In all studies except two the isotime is defined as the time at which the placebo test ended. Oxygen improved breathlessness, SaO2/PaO2 and VE at isotime with endurance exercise testing. There was no data on breathlessness at isotime with maximal exercise testing. Oxygen improved SaO2/PaO2 and reduced VE at Isotime.

Authors' conclusions: This review provides some evidence from small, single assessment studies that ambulatory oxygen improves exercise performance in people with moderate to severe COPD. The results of the review may be affected by publication bias, and the small sample sizes in the studies. Although positive, the findings of the review require replication in larger trials with more distinct subgroups of participants. Maximal or endurance tests can be used in ambulatory oxygen assessment. Consideration should be given to the measurement of SaO2 and breathlessness at isotime as these provide important additional information. We recommend that these outcomes are included in the assessment for ambulatory oxygen. Future research needs to establish the level of benefit of ambulatory oxygen in specific subgroups of people with COPD.

Conflict of interest statement

There are no known conflicts of interest.

Figures

1
1
Forest plot of comparison: 1 Oxygen versus placebo (crossover studies), outcome: 1.1 Endurance test ‐ exercise distance (Davidson 1988 6MWT).
2
2
Forest plot of comparison: 1 Oxygen versus placebo (crossover studies), outcome: 1.2 Endurance test ‐ exercise distance (Davidson 1988 endurance walk).
3
3
Funnel plot of exercise distance (Comparison 01; outcome 01). The blue dots represent the mean differences of individual trial estimates. The distribution of these dots to the right of the dotted line suggests that there may be the equivalent number of 'negative' trials that have not been included in this analysis.
4
4
Funnel plot of exercise distance (Comparison 01; outcome 03). The blue dots represent the mean differences of individual trials. The distribution of these dots to the right of the dotted line suggests that there may be the equivalent number of 'negative' trials that have not been included in this analysis.
1.1. Analysis
1.1. Analysis
Comparison 1 Oxygen versus placebo (crossover studies), Outcome 1 Endurance test ‐ exercise distance (Davidson 1988 6MWT).
1.2. Analysis
1.2. Analysis
Comparison 1 Oxygen versus placebo (crossover studies), Outcome 2 Endurance test ‐ exercise distance (Davidson 1988 endurance walk).
1.3. Analysis
1.3. Analysis
Comparison 1 Oxygen versus placebo (crossover studies), Outcome 3 Endurance test ‐ exercise time (Davidson 1988 low dose cycle data/Somfay 2001 low dose).
1.4. Analysis
1.4. Analysis
Comparison 1 Oxygen versus placebo (crossover studies), Outcome 4 Endurance test ‐ exercise time (Davidson 1988 high dose cycle/Somfay 2001 high dose).
1.5. Analysis
1.5. Analysis
Comparison 1 Oxygen versus placebo (crossover studies), Outcome 5 Endurance test ‐ exercise time (Davidson 1988 low dose end'rnce walk/Somfay 2001 low dose).
1.6. Analysis
1.6. Analysis
Comparison 1 Oxygen versus placebo (crossover studies), Outcome 6 Endurance test ‐ exercise time (change from baseline).
1.7. Analysis
1.7. Analysis
Comparison 1 Oxygen versus placebo (crossover studies), Outcome 7 Endurance test ‐ exercise steps.
1.8. Analysis
1.8. Analysis
Comparison 1 Oxygen versus placebo (crossover studies), Outcome 8 Maximal test ‐ exercise distance.
1.9. Analysis
1.9. Analysis
Comparison 1 Oxygen versus placebo (crossover studies), Outcome 9 Maximal test ‐ exercise time.
1.10. Analysis
1.10. Analysis
Comparison 1 Oxygen versus placebo (crossover studies), Outcome 10 Maximal test ‐ exercise VO2max (SMD).
1.11. Analysis
1.11. Analysis
Comparison 1 Oxygen versus placebo (crossover studies), Outcome 11 Maximal test ‐ wattage output.
1.12. Analysis
1.12. Analysis
Comparison 1 Oxygen versus placebo (crossover studies), Outcome 12 Endurance test ‐ isotime breathlessness (Somfay 2001 low dose).
1.13. Analysis
1.13. Analysis
Comparison 1 Oxygen versus placebo (crossover studies), Outcome 13 Endurance test ‐ isotime breathlessness (Somfay 2001 high dose).
1.14. Analysis
1.14. Analysis
Comparison 1 Oxygen versus placebo (crossover studies), Outcome 14 Endurance test ‐ isotime SaO2 (Somfay 2001 low dose).
1.15. Analysis
1.15. Analysis
Comparison 1 Oxygen versus placebo (crossover studies), Outcome 15 Endurance test ‐ isotime SaO2 (Somfay 2001 high dose).
1.16. Analysis
1.16. Analysis
Comparison 1 Oxygen versus placebo (crossover studies), Outcome 16 Endurance test ‐ isotime PaO2.
1.17. Analysis
1.17. Analysis
Comparison 1 Oxygen versus placebo (crossover studies), Outcome 17 Endurance test ‐ isotime ventilation (Somfay low dose).
1.18. Analysis
1.18. Analysis
Comparison 1 Oxygen versus placebo (crossover studies), Outcome 18 Endurance test ‐ isotime ventilation (Somfay high dose).
1.19. Analysis
1.19. Analysis
Comparison 1 Oxygen versus placebo (crossover studies), Outcome 19 Maximal test ‐ isotime SaO2.
1.20. Analysis
1.20. Analysis
Comparison 1 Oxygen versus placebo (crossover studies), Outcome 20 Maximal test ‐ isotime PaO2.
1.21. Analysis
1.21. Analysis
Comparison 1 Oxygen versus placebo (crossover studies), Outcome 21 Maximal test ‐ isotime ventilation.
1.22. Analysis
1.22. Analysis
Comparison 1 Oxygen versus placebo (crossover studies), Outcome 22 Endurance test VO2.
2.1. Analysis
2.1. Analysis
Comparison 2 SUBGROUP ANALYSES: mean baseline kPa/PaO2 & high dose versus low dose studies), Outcome 1 MEAN BASELINE PAO2 > 7.3kPa/55mmHG: Endurance test ‐ exercise distance.
2.2. Analysis
2.2. Analysis
Comparison 2 SUBGROUP ANALYSES: mean baseline kPa/PaO2 & high dose versus low dose studies), Outcome 2 MEAN BASELINE PAO2 > 7.3kPa/55mmHG: Endurance test ‐ exercise time.
2.3. Analysis
2.3. Analysis
Comparison 2 SUBGROUP ANALYSES: mean baseline kPa/PaO2 & high dose versus low dose studies), Outcome 3 MEAN BASELINE PAO2 > 7.3kPa/55mmHG: Maximal test ‐ exercise distance.
2.4. Analysis
2.4. Analysis
Comparison 2 SUBGROUP ANALYSES: mean baseline kPa/PaO2 & high dose versus low dose studies), Outcome 4 MEAN BASELINE PAO2 > 7.3kPa/55mmHG: Maximal test ‐ exercise time.
2.5. Analysis
2.5. Analysis
Comparison 2 SUBGROUP ANALYSES: mean baseline kPa/PaO2 & high dose versus low dose studies), Outcome 5 MEAN BASELINE PAO2 > 7.3kPa/55mmHG: Maximal test ‐ exercise VO2max (SMD).
2.6. Analysis
2.6. Analysis
Comparison 2 SUBGROUP ANALYSES: mean baseline kPa/PaO2 & high dose versus low dose studies), Outcome 6 MEAN BASELINE PAO2 > 7.3kPa/55mmHG: Endurance test ‐ isotime breathlessness.
2.7. Analysis
2.7. Analysis
Comparison 2 SUBGROUP ANALYSES: mean baseline kPa/PaO2 & high dose versus low dose studies), Outcome 7 MEAN BASELINE PAO2 > 7.3kPa/55mmHG: Maximal test ‐ isotime ventilation.
2.8. Analysis
2.8. Analysis
Comparison 2 SUBGROUP ANALYSES: mean baseline kPa/PaO2 & high dose versus low dose studies), Outcome 8 HIGH DOSE VERSUS LOW DOSE: Endurance test ‐ exercise time (Davidson imputed SEM).
2.9. Analysis
2.9. Analysis
Comparison 2 SUBGROUP ANALYSES: mean baseline kPa/PaO2 & high dose versus low dose studies), Outcome 9 HIGH DOSE VERSUS LOW DOSE: Endurance test ‐ isotime breathlessness.
2.10. Analysis
2.10. Analysis
Comparison 2 SUBGROUP ANALYSES: mean baseline kPa/PaO2 & high dose versus low dose studies), Outcome 10 HIGH DOSE VERSUS LOW DOSE: Endurance test ‐ isotime SaO2.
2.11. Analysis
2.11. Analysis
Comparison 2 SUBGROUP ANALYSES: mean baseline kPa/PaO2 & high dose versus low dose studies), Outcome 11 HIGH DOSE VERSUS LOW DOSE: Endurance test ‐ isotime ventilation.
2.13. Analysis
2.13. Analysis
Comparison 2 SUBGROUP ANALYSES: mean baseline kPa/PaO2 & high dose versus low dose studies), Outcome 13 MEAN BASELINE PA02> 7.3kPa/55mmHg: Maximal test‐ wattage.

Source: PubMed

3
Sottoscrivi